


PENDING CLAIMS IN APPLICATION S.N. 09/472,126

17. (New) A device for the controlled release over a prolonged period of time of a drug having antiprogestinic properties, said device comprising a core comprising said drug and optionally a membrane encasing said core, said core and/or membrane being made of a siloxane-based elastomer composition comprising at least one elastomer and optionally a non-crosslinked polymer, wherein said elastomer composition comprises poly(alkylene oxide) groups and the poly(alkylene oxide) groups are present in the elastomer or polymer as alkoxy-terminated grafts of polysiloxane units, or as blocks, the said grafts or blocks being linked to the polysiloxane units by silicon-carbon bonds, or as a mixture of these forms, said poly(alkylene oxide) groups having the formula




where R is hydrogen or lower alkyl, R_3 is a linear or branched C_2-C_6 alkylene group and m is from 1 to 3.

18. (New) The device according to claim 17, wherein the core is an elastomer matrix, optionally made of said elastomer composition.

19. (New) The device according to claim 18, wherein the membrane or matrix is made of an elastomer based on polysiloxane units which comprise poly(alkylene oxide) groups.

20. (New) The device according to claim 17, wherein in the elastomer composition the poly(alkylene oxide) groups are poly(ethylene oxide) groups (PEO groups).

21. (Twice Amended) The device according to claim 17, wherein the formula of the polysiloxane groups is




where some of the substituents R' and R'' are

- free groups which are the same or different and which are a lower alkyl group or a phenyl group in which case the said alkyl group may be substituted or unsubstituted, or alkoxy terminated poly(alkylene oxide) groups having the formula $-\text{R}_3-\text{O}-(\text{CHRCH}_2\text{O})_m-\text{alk}$, where alk is a lower alkyl group, R is hydrogen or lower alkyl, R_3 is a linear or branched C_2-C_6 alkylene and m is 1 to 30,
- bonds formed from the hydrogen or alkenyl groups to other polymer chains in the elastomer, and
- optionally unreacted groups selected from the group consisting of hydrogen, vinyl and vinyl-terminated alkenyl, and
- q is 1 to 3000.

22. (Once Amended) The device according to claim 21, wherein the free R' and R'' groups are lower alkyl groups.

23. (New) The device according to claim 17, wherein the poly(alkylene oxide) groups are present in the elastomer in the form of poly(alkylene oxide) blocks having the formula



where R is hydrogen, a lower alkyl or phenyl, R₁ is hydrogen or lower alkyl, R₃ and R₄ are the same or different and are linear or branched C₂-C₆ alkylene and m is 1 to 30.

24. (Once Amended) The device according to claim 17, wherein the elastomer composition is made up of two elastomers interlaced one inside the other, in which case

- the first elastomer comprises poly(alkylene oxide) groups and that the poly(alkylene oxide) groups are present in the said elastomer as alkoxy-terminated grafts of polysiloxane units, or as blocks in which case the said grafts or blocks are linked to the polysiloxane units by silicon carbon bonds, or as a mixture of these forms, and that
- the second elastomer is a siloxane elastomer.

25. (Once Amended) The device according to claim 24, wherein the second elastomer is a poly(dimethyl siloxane) elastomer which optionally comprises poly(alkylene oxide) groups.

26. (Once Amended) The device according to claim 25, wherein said second poly(dimethyl siloxane) elastomer contains poly(alkylene oxide) groups, which are present in the form of alkoxy-terminated grafts of poly(dimethyl siloxane) units, or as blocks in which case the said grafts or blocks are linked to the poly(dimethyl siloxane) units by silicon carbon bonds, or as a mixture of these forms.

27. (Once Amended) The device according to claim 17, wherein the elastomer composition is a blend, which comprises

- a siloxane elastomer and
- a linear polysiloxane copolymer which comprises poly(alkylene oxide) groups in which case the poly(alkylene oxide) groups are present in the said polymer as alkoxy-terminated grafts of polysiloxane units, or as blocks in which case the said grafts or blocks are linked to the polysiloxane units by silicon carbon bonds, or as a mixture of these forms.

28. (New) The device according to claim 18, wherein the matrix is encased in a membrane.

29. (New) The device according to claim 28, wherein the matrix and the membrane both are made of an elastomer composition comprising poly(alkylene oxide) groups and the poly(alkylene oxide) groups are present in the elastomer or polymer as alkoxy-terminated grafts of polysiloxane units, or as blocks, the said grafts or blocks being linked to the polysiloxane units by silicon-carbon bonds or as a mixture of these forms.

30. (New) The device according to claim 17, wherein the device is an implant, an intrauterine or intracervical device, an intravaginal device, or a transdermal patch.

31. (New) The device according to claim 17, wherein the drug having antiprogestinic properties is a compound selected from a group consisting of

11beta-[(4-Dimethylamino)phenyl]-17beta-hydroxy-17alpha-(1-propinyl)-4,9-estradien-3-one (mifepristone);

11beta-[(4-Dimethylamino)phenyl]-17beta-hydroxy-17alpha-(1-propinyl)-18-homoestra-4,9-dien-3-one;

11beta-[(4-Dimethylamino)phenyl]-17beta-hydroxy-17alpha-(1-propinyl)-17a-homoestra-4,9,16-trien-3-one;

11beta-[(4-Dimethylamino)phenyl]-17alpha-hydroxy-17beta-(3-hydroxypropyl)-13 α -methyl-estra-4,9-dien-3-one (onapristone);

(Z)-11beta-[(4-Dimethylamino)phenyl]-17beta-hydroxy-17alpha-(3-hydroxy-1-propenyl)estra-4,9-dien-3-one (lilopristone);

11beta-(4-Acetylphenyl)-17beta-hydroxy-17alpha-(1-propenyl)estra-4,9-dien-3-one;

(Z)beta-(4-Acetylphenyl)-17beta-hydroxy-17alpha-(3-hydroxy-1-propenyl)estra-4,9-dien-3-one;

11beta-(4-Methoxyphenyl)-17beta-hydroxy-17alpha-ethynyl-4,9-estradien-3-one;

(Z)-11beta-[(4-Dimethylamino)phenyl]-17beta-hydroxy-17alpha-(3-hydroxy-1-propenyl)estr-4-en-3-one;

4-[17β-Methoxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1-(E)-oxime;

4-[17β-Hydroxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1-(E)-oxime;

4-[17β-Methoxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1-(E)-[O-(ethylamino)carbonyl]oxime;

4-[17β-Methoxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1-(E)-[O-(ethoxy)carbonyl]oxime;

4-[17β-Methoxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1-(E)-[O-(ethylthio)carbonyl]oxime;

4-[17β-Methoxy-17α-(ethoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1-(E)-[O-(ethylthio)carbonyl]oxime;

4-[17β-Hydroxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1-(E)-[O-(n-propylthio)carbonyl]oxime;

(Z)-6'-(4-cyanophenyl)-9,11 α -dihydro-17 β -hydroxy-17 α -[4-(1-oxo-3-methylbutoxy)-1-butenyl]-4'H-naphtho[3',2',1';10,9,11]estra-4-en-3-one;

(Z)-6'-(4-cyanophenyl)-9,11 α -dihydro-17 β -hydroxy-17 α -[3-(1-oxo-3-methylbutoxy)-1-propenyl]-4'H-naphtho[3',2',1';10,9,11]estra-4,15-dien-3-one;

(Z)-6'-(4-cyanophenyl)-9,11 α -dihydro-17 β -hydroxy-17 α -(3-hydroxy-1-propenyl)-4'H-naphtho[3',2',1';10,9,11]estra-4,15-dien-3-one;

(Z)-6'-(3-pyridinyl)-9,11 α -dihydro-17 β -hydroxy-17 α -(3-hydroxy-1-propenyl)-4'H-naphtho[3',2',1';10,9,11]estra-4,15-dien-3-one;

11 β -(4-Acetylphenyl)-17 β -hydroxy-17 α -(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one;

6'-(Acetyloxy)-9,11 α -dihydro-17 β -hydroxy-17 α -(1,1,2,2,2-pentafluoroethyl)-4'H-naphth[3',2',1':10,9,11] estr-4-en-3-one;

9,11 α -(Dihydro)-17 β -hydroxy-6'-(hydroxymethyl)-17 α -(1,1,2,2,2-pentafluoroethyl)-4'H-naphth[3',2',1':10,9,11] estr-4-en-3-one;

11 β -(4-Acetylphenyl)-19,24-dinor-17,23-epoxy-17 α -chola-4,9,20-trien-3-one;

11 β -(4-Methoxyphenyl)-19,24-dinor-17,23-epoxy-17 α -chola-4,9,20-trien-3-one;

(Z)-11 β ,19-[4-(3-Pyridinyl)-o-phenylene]-17 β -hydroxy-17 α -[3-hydroxy-1-propenyl]-4-androsten-3-one;

(2)-11beta,19-[4-(4-Cyanophenyl-o-phenylene)]-17beta-hydroxy-17alpha-[3-hydroxy-1-propenyl]-4-androsten-3-one;

11beta-[4-(1-methylethenyl)phenyl]-17alpha-hydroxy-17beta-(3-hydroxypropyl)-13alpha-estra-4,9-dien-3-one;

11beta-[4-(3-Furanyl)phenyl]-17alpha-hydroxy-17beta-(3-hydroxypropyl)-13alpha-estra-4,9-dien-3-one;

4',5'-Dihydro-11beta-[4-(dimethylamino)phenyl]-6beta-methylspiro[estra-4,9-dien-17beta,2'(3'H)-furan]-3-one;

4',5'-Dihydro-11beta-[4-(dimethylamino)phenyl]-7beta-methylspiro[estra-4,9-dien-17beta,2'(3'H)-furan]-3-one;

4-beta,17alpha-Dimethyl-17beta-hydroxy-3-oxo-4alpha,5-epoxy-5alpha-androstan-2alpha-carbonitrile;

7alpha-[9-(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-trien-3,17 beta-diol;

3-(4-chloro-3-trifluoromethylphenyl)-1-(4-iodobenzenesulfonyl)-1,4,5,6-tetrahydropyridazine;

(R,S)3-(4-chloro-3-trifluoromethylphenyl)-1-(iodobenzenesulfonyl)-6-methyl-1,4,5,6-tetrahydropyridazine;

3-(3,4-dichlorophenyl)-1-(3,5-dichlorobenzoyl)-1,4,5,6-tetrahydropyridazine;

3-(3,4-dichlorophenyl)-1-(2,5-dichlorobenzenesulfonyl)-1,4,5,6-tetrahydropyridazine;

7,8-Dibromo-3,4-diazo-1,2,3,10,10a-hexahydro-3-(4-iodobenzenesulfonyl)-phenanthrene; and

7Chloro-3,4-diazo-1,2,3,9,10,10a-hexahydro-3-(2,5-dichlorobenzenesulfonyl)-phenanthrene.